Get the Stockscreener App
8.10
0.87%
0.07
After Hours:
8.15
0.05
+0.62%
Novavax Inc stock is traded at $8.10, with a volume of 3.58M.
It is up +0.87% in the last 24 hours and up +5.19% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$8.03
Open:
$8.1
24h Volume:
3.58M
Relative Volume:
0.89
Market Cap:
$1.33B
Revenue:
$1.12B
Net Income/Loss:
$440.30M
P/E Ratio:
3.4026
EPS:
2.3805
Net Cash Flow:
$-251.02M
1W Performance:
+2.27%
1M Performance:
+5.19%
6M Performance:
+5.33%
1Y Performance:
+29.19%
1-Day Range:
$7.812
$8.16
1-Week Range:
$7.71
$8.355
52-Week Range:
$5.80
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.10 | 1.32B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax earnings in focus: Safety edge meets steep revenue test By Investing.com - Investing.com Nigeria
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Attachment - GlobeNewswire
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now? - Insider Monkey
Vanguard reports 8.31M-share stake in Novavax (NVAX) - Stock Titan
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Novavax investors get first-quarter 2026 results at 8:30 a.m. May 6 - Stock Titan
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026 - Yahoo Finance
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) director exercises RSUs for 9,520 common shares - Stock Titan
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax Q2 2025 Earnings Preview - MSN
Bank of America reports 4.1% Novavax stake (NASDAQ: NVAX) - Stock Titan
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NASDAQ: NVAX) details 2026 proxy, board slate and equity share increases - Stock Titan
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
NVAX stock rises overnight ahead of Q4 print with Pfizer tailwinds — analyst warns of 20% crash - MSN
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Avoiding Lag: Real-Time Signals in (NVAX) Movement - Stock Traders Daily
Novavax Q3 2025 Earnings Preview - MSN
Cash-Rich Stocks: 10x Genomics, Novavax, and Powell Analysis | April 2026News and Statistics - IndexBox
Is Novavax (NVAX) Now Pricing In Too Much Risk After Its Recent Volatility - Yahoo Finance
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026News and Statistics - IndexBox
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead - Insider Monkey
FY2028 EPS Estimates for Novavax Cut by Zacks Research - MarketBeat
1 Cash-Heavy Stock to Target This Week and 2 We Ignore - The Globe and Mail
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Earnings snapshot: Novavax tops Q2 estimates; raises full-year outlook - MSN
5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
Is Novavax (NVAX) stock a good investment this year | Novavax Inc. posts 122% EPS beat vs expected lossProfit Guidance - Xã Thanh Hà
US CDC will not publish report showing COVID vaccine effectiveness - Reuters
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs? - TradingView
Will Higher Costs & Lower Occupancy Impact HCA's Q1 Earnings? - TradingView
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best - Yahoo Finance
H.C. Wainwright reiterates Novavax stock rating on vaccine study By Investing.com - Investing.com India
H.C. Wainwright reiterates Novavax stock rating on vaccine study - Investing.com
Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News
Novavax’s COVID vaccine becomes 4th available for use in Japan - 朝日新聞
Novavax Urged to Probe Studies Using Monkeys From Filthy Lab After PETA Exposé - PETA
Novavax (NVAX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Novavax (NVAX) EVP R&D discloses options, RSUs and shares on Form 3 - Stock Titan
Discipline and Rules-Based Execution in NVAX Response - Stock Traders Daily
Novavax Inc stock (US6707721049): Is its vaccine pipeline strong enough to unlock new upside? - AD HOC NEWS
SHAH CAPITAL MANAGEMENT Increases Stake in Novavax Inc - GuruFocus
Novavax Inc stock (US6707721049): Is its vaccine pivot strong enough to unlock new upside? - AD HOC NEWS
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):